ClinicalTrials.gg
RecruitingNCT07615764Updated Nov 3, 2026

An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial

An interventional study of Educational Intervention and Educational Intervention in Lung Carcinoma, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Prevention

How we know

Updated Nov 3, 2026Now RecruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center — 6 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Fred Hutchinson Cancer Center.

Planned enrollment
5th of 12
60 · median 52
Started
2026
with 3 others
No phase
8 of 13
4 open now
Registered
13th of 13
by date

Among the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 with no phase, and was the 13th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lung Neoplasms by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial evaluates the acceptability and effectiveness of an educational intervention (Lung Toolkit) for improving knowledge about lung cancer and lung cancer screening among American Indian/Alaskan Native (AI/AN) cigarette smokers. The Lung Toolkit is an educational intervention, including a website and a physical artifact pouch, specifically tailored to the needs of AI/AN individuals. The website includes evidence-based resources about lung health and lung cancer screening, facts about commercial tobacco and traditional tobacco, national and local smoking cessation and screening resources, and community-building resources such as stories from AI/AN community members about their experiences with lung cancer screening and smoking cessation. The physical artifact pouch links to the website with a quick response code and contains ceremonial herbs and motivational messaging around smoking cessation and lung cancer screening. The Lung Toolkit intervention may be effective for improving knowledge about lung cancer screening and commercial tobacco cessation in AI/AN populations.

Read the detailed description

OUTLINE:

Participants receive the Lung Toolkit materials, including a link to the lung health toolkit website and a physical artifact pouch, and then receive a guided review of the Lung Toolkit materials over 60 minutes. Following the guided review, participants use the Lung Toolkit materials for 30 days.

03

Conditions studied

  • Lung Carcinoma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between ages 50-80
  • Self-identify as AI/AN
  • Self-reported 10 pack-year smoking history (commercial tobacco i.e. cigarettes)
  • Ability to understand and indicate

Exclusion criteria

Exclusion Criteria:

  • Not between ages 50-80
  • Having less than a 10 pack-year history of smoking commercial tobacco
  • Inability to communicate in written and verbal English
  • Having any cognitive impairment that compromises the ability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Prevention (Lung Toolkit)

    Participants receive the Lung Toolkit materials, including a link to the lung health toolkit website and a physical artifact pouch, and then receive a guided review of the Lung Toolkit materials over 60 minutes. Following the guided review, participants use the Lung Toolkit materials for 30 days.

    Other: Educational Intervention · Other: Interview · Other: Questionnaire Administration

Interventions

  • OtherEducational Intervention

    Receive Lung Toolkit materials

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherEducational Intervention

    Receive guided review of Lung Toolkit materials

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • OtherInterview

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Acceptability of intervention

    Acceptability will be evaluated using the Acceptability of Intervention (AIM) assessment score and semi-structured interviews. AIM results will be summarized and presented as a range of score from 1 to 5.

    Time frame: At post-guided review assessment (day 15) and post-intervention (day 45)

  2. Lung cancer screening knowledge

    Will be evaluated using a validated measure for assessing lung cancer screening knowledge (Lung Cancer Screening Knowledge Score \[LKS\]-7). Pre- and post-intervention LKS responses will be compared via Cochran-Mantel-Haenszel and Friedman tests.

    Time frame: From baseline to day 45

Secondary outcomes

  1. User engagement

    The effectiveness of the website in terms of engagement will be measured by tracking of bounce rate (percentage of visitors who land on website homepage and leave immediately without taking any further action, or viewing other pages).

    Time frame: During 30-day use period

  2. User behavior

    Participant behavior, and how participants navigate the website will be measured through click tracking (tracking of where users click on a website).

    Time frame: During 30-day use period

  3. Medical mistrust

    The intervention efficacy potential to mitigate medical mistrust will be evaluated using validated measures of discrimination and medical mistrust (Discrimination in Medical Settings; Group-Based Medical Mistrust Scale). Participant responses for each scale will be summarized with the median and range of scores at pre- and post-intervention.

    Time frame: From baseline to day 45

  4. Perceived smoking-related stigma

    The intervention efficacy potential to reduce perceived smoking-related stigma will be evaluated using a validated measure of perceived smoking-related stigma (Cataldo Lung Cancer Stigma Scale, smoking-related subscale). Participant responses for each scale will be summarized with the median and range of scores at pre- and post-intervention.

    Time frame: From baseline to day 45

  5. Self-efficacy for lung cancer screening

    The intervention efficacy potential to improve self-efficacy for lung cancer screening will be evaluated using a validated 9-item measure assessing self-efficacy for lung cancer screening. Participant responses for each scale will be summarized with the median and range of scores at pre- and post-intervention.

    Time frame: From baseline to day 45

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 3 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Dec 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 29, 2026
StartEst.
Dec 1, 2026was Nov 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
Fred Hutch/University of Washington Cancer Consortium is now Recruiting
Oct 16, 2026
Start date
Nov 1, 2026→Dec 1, 2026
Nov 3, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAbility to understand and willingness to sign anindicate informed consent document
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Start date Nov 1, 2026→Dec 1, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAbility to understand and willingness to sign anindicate informed consent document
    + 2 other changes: verification date and description
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    Fred Hutch/University of Washington Cancer Consortium is now Recruiting
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07615764
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Nicolas Anderson
Contact
nanders3@fredhutch.org
206.667.5434
Matthew Triplette, MD, MPH
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion